ATE84799T1 - Biologisch wirksames lipoprotein und seine verwendung. - Google Patents

Biologisch wirksames lipoprotein und seine verwendung.

Info

Publication number
ATE84799T1
ATE84799T1 AT89850346T AT89850346T ATE84799T1 AT E84799 T1 ATE84799 T1 AT E84799T1 AT 89850346 T AT89850346 T AT 89850346T AT 89850346 T AT89850346 T AT 89850346T AT E84799 T1 ATE84799 T1 AT E84799T1
Authority
AT
Austria
Prior art keywords
lipoprotein
pharmaceutical composition
biologically active
patient
active lipoprotein
Prior art date
Application number
AT89850346T
Other languages
English (en)
Inventor
Tore Curstedt
Bjoern Loewenadler
Hans Joernvall
Bengt Robertsson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20373667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE84799(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Application granted granted Critical
Publication of ATE84799T1 publication Critical patent/ATE84799T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT89850346T 1988-10-18 1989-10-11 Biologisch wirksames lipoprotein und seine verwendung. ATE84799T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE19888803713A SE8803713D0 (sv) 1988-10-18 1988-10-18 Biologically active lipoprotein and its use
EP89850346A EP0368823B2 (de) 1988-10-18 1989-10-11 Biologisch wirksames Lipoprotein und seine Verwendung

Publications (1)

Publication Number Publication Date
ATE84799T1 true ATE84799T1 (de) 1993-02-15

Family

ID=20373667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89850346T ATE84799T1 (de) 1988-10-18 1989-10-11 Biologisch wirksames lipoprotein und seine verwendung.

Country Status (8)

Country Link
US (2) US5223481A (de)
EP (1) EP0368823B2 (de)
JP (1) JP2963923B2 (de)
AT (1) ATE84799T1 (de)
AU (1) AU623180B2 (de)
CA (1) CA2000893C (de)
DE (1) DE68904530T3 (de)
SE (1) SE8803713D0 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU616685B2 (en) * 1987-09-01 1991-11-07 Teijin Limited Method for assaying human lung surface active substance
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
EP0482097B1 (de) * 1989-07-11 2001-06-06 Genentech, Inc. Oberflächenaktive zusammensetzungen und verfahren
CA2063273C (en) * 1989-07-11 2002-09-24 Bradley J. Benson Surfactant compositions and methods
DE69125750D1 (de) * 1990-05-21 1997-05-28 Abbott Lab Fettsäure-Oberflächenaktives-Lungenprotein Konjate
US5258496A (en) * 1990-07-10 1993-11-02 Scios Nova Inc. Isolation and purification of lung surfactant protein
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
JP3961029B2 (ja) * 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
ES2189825T3 (es) * 1993-12-08 2003-07-16 Mitsubishi Pharma Corp Nuevo peptido sintetico, tensioactivo pulmonar que lo contiene y remedio para el sindrome de malestar respiratorio.
DE4418936A1 (de) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
FR2739860B1 (fr) * 1995-10-17 1998-01-02 Coletica Complexes amphiphiles, procede pour leur preparation et compositions en renfermant
JP4181216B2 (ja) * 1996-05-15 2008-11-12 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 薄層クロマトグラフィーを用いる疎水性蛋白質の分離及び分析法
US6476191B1 (en) 1999-02-05 2002-11-05 Mixture Sciences, Inc. Volatilizable solid phase supports for compound synthesis
IT1308180B1 (it) * 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
CA2384861A1 (en) 1999-09-16 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
ES2346048T3 (es) 2001-10-11 2010-10-08 Nycomed Gmbh Nueva utilizacion de un agente tensioactivo pulmonar.
US8236750B2 (en) 2004-08-06 2012-08-07 Nycomed Gmbh Composition comprising a pulmonary surfactant and a TNF-derived peptide
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
EP1841458B9 (de) 2005-01-06 2012-12-12 Discovery Laboratories, Inc. Dosierungsschema unter verwendung eines tensids zur behandlung oder verhinderung von lungendysplasien
JP2007309695A (ja) * 2006-05-16 2007-11-29 Univ Of Tokyo 質量分析のための脂質修飾ペプチドの抽出方法
CA2663795A1 (en) * 2006-09-19 2008-03-27 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
WO2008151235A2 (en) * 2007-06-05 2008-12-11 Forma Therapeutics, Inc. Compositions for delivering medicaments into the lungs, uses thereof
WO2010068754A2 (en) 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234475A (en) * 1975-08-15 1980-11-18 The Gillette Company Reacting protein with organic acid
DE2925942A1 (de) * 1979-06-27 1981-01-22 Bayer Ag Disazokupferkomplex-reaktivfarbstoffe
US4406833A (en) * 1982-06-04 1983-09-27 Fats And Proteins Research Foundation, Inc. Surfactants derived from fatty acid esters and proteinaceous material
US4933280A (en) * 1984-12-11 1990-06-12 California Biotechnology Inc. Recombinant DNA sequence encoding Alveolar Surfactant Protein
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US4918161A (en) * 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
US4882422A (en) * 1985-10-24 1989-11-21 Genetics Institute, Inc. Pulmonary surfactant proteins
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
WO1987006943A1 (en) * 1986-05-06 1987-11-19 Children's Hospital Medical Center Pulmonary hydrophobic surfactant-associated protein of 6,000 daltons molecular weight and multimers thereof
WO1988003170A1 (en) * 1986-10-24 1988-05-05 Whitsett Jeffrey A Pulmonary hydrophobic surfactant-associated proteins
JPH01501282A (ja) * 1986-12-08 1989-05-11 ホイツトセツト，ジエフリー　エイ． 肺胞疎水性界面活性物質関連タンパク質
IT1203873B (it) * 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
WO1989000167A1 (en) * 1987-07-01 1989-01-12 Kabigen Ab Proteins and protein compositions and their use
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US4993280A (en) * 1989-07-17 1991-02-19 Motorola, Inc. Rotational control assembly

Also Published As

Publication number Publication date
EP0368823A3 (en) 1990-05-23
DE68904530D1 (de) 1993-03-04
CA2000893A1 (en) 1990-04-18
AU4299689A (en) 1990-04-26
JPH02145599A (ja) 1990-06-05
EP0368823A2 (de) 1990-05-16
JP2963923B2 (ja) 1999-10-18
AU623180B2 (en) 1992-05-07
DE68904530T2 (de) 1993-07-29
CA2000893C (en) 2000-08-08
EP0368823B1 (de) 1993-01-20
EP0368823B2 (de) 1998-12-23
US5223481A (en) 1993-06-29
SE8803713D0 (sv) 1988-10-18
DE68904530T3 (de) 1999-07-08
US5455227A (en) 1995-10-03

Similar Documents

Publication Publication Date Title
ATE84799T1 (de) Biologisch wirksames lipoprotein und seine verwendung.
DK1201241T3 (da) Sammensætninger indeholdende capsaicin eller capsaicinanaloge og et bedøvelsesmiddel
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE3483055D1 (de) Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms.
DE69933877D1 (de) Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung
FR2695317B1 (fr) Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.
DK0725648T3 (da) Leverspecifikke farmaceutiske aktivstoffer
EP0210189A4 (de) Rekombinantes alveolares oberflächenaktives protein.
BR8603315A (pt) Processo para produzir um implante de liberacao controlada;implante usado no processo;processo para purificar e concentrar hormonio de crescimento biologicamente ativo em uma forma adequada para incorporacao em um implante para administracao subcutanea
NO954691D0 (no) Reduksjon av liposom-indusert ugunstige fysiologiske reaksjoner
DE68912589D1 (de) Mittel zur verbesserung des fettabbaus und verfahren zur verwendung.
EP1264612A1 (de) Verfahren zur nasalen Verabreichung von einem Medikament
ATE88633T1 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
ATE183651T1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
ATE258933T1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
BE894185A (fr) Formulations pharmaceutiques comprenant de l'insuline humaine et du c-peptide humain
DE69021257D1 (de) Verwendung von IFN-gamma zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von ATL.
ATE94763T1 (de) Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung.
FR2635527B1 (fr) Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
EP1435994B1 (de) Neue verwendung von lungensurfactant
DE69919969D1 (de) Humanes Wachstumshormon zur Stimulierung der Hämatopoese und der Immunrekonstitution nach hämatopoetischer Stammzelltransplantation beim Menschen
Code et al. Expansion of stimulus-evoked metabolic activity in monkey somatosensory cortex after peripheral denervation
GB2198351B (en) Improvements in or relating to the use of epidermal growth factor for enhancing the uptake of iron in vivo.
ES2092969A1 (es) Surfactante pulmonar natural de origen porcino.
ATE40795T1 (de) Verwendung eines zerebral und peripher wirkenden antihypoxidotikums.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee